New York State Common Retirement Fund
RVNC

New York State Common Retirement Fund’s Revance Therapeutics, Inc. RVNC Stock Holding History

New York State Common Retirement Fund’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31,338
Closed -$95.3K – 3208
2024
Q4 		$95.3K Hold
31,338
– – ﹤0.01% 2615
2024
Q3 		$163K Hold
31,338
– – ﹤0.01% 2392
2024
Q2 		$80.5K Buy
31,338
+62
+0.2% +$212 ﹤0.01% 2955
2024
Q1 		$154K Sell
31,276
-4,264
-12% -$25.2K ﹤0.01% 2556
2023
Q4 		$312K Buy
35,540
+1,857
+6% +$15.2K ﹤0.01% 2273
2023
Q3 		$386K Buy
33,683
+229
+0.7% +$4.4K ﹤0.01% 2158
2023
Q2 		$847K Sell
33,454
-9,036
-21% -$281K ﹤0.01% 1852
2023
Q1 		$1.37M Sell
42,490
-10,118
-19% -$315K ﹤0.01% 1732
2022
Q4 		$971K Buy
52,608
+2,010
+4% +$46K ﹤0.01% 1985
2022
Q3 		$1.37M Buy
50,598
+111
+0.2% +$2.25K ﹤0.01% 1809
2022
Q2 		$698K Sell
50,487
-135
-0.3% -$2.08K ﹤0.01% 2194
2022
Q1 		$987K Buy
50,622
+23
+0% +$349 ﹤0.01% 2114
2021
Q4 		$826K Sell
50,599
-135
-0.3% -$2.25K ﹤0.01% 2181
2021
Q3 		$1.41M Sell
50,734
-10,084
-17% -$288K ﹤0.01% 1953
2021
Q2 		$1.8M Buy
60,818
+3,718
+7% +$107K ﹤0.01% 1933
2021
Q1 		$1.6M Hold
57,100
– – ﹤0.01% 1910
2020
Q4 		$1.62M Buy
57,100
+5,000
+10% +$130K ﹤0.01% 1791
2020
Q3 		$1.31M Hold
52,100
– – ﹤0.01% 1779
2020
Q2 		$1.27M Buy
52,100
+8,200
+19% +$162K ﹤0.01% 1748
2020
Q1 		$650K Buy
43,900
+4,400
+11% +$91K ﹤0.01% 1928
2019
Q4 		$641K Sell
39,500
-7,600
-16% -$118K ﹤0.01% 2167
2019
Q3 		$612K Hold
47,100
– – ﹤0.01% 2223
2019
Q2 		$611K Buy
47,100
+15,600
+50% +$197K ﹤0.01% 2265
2019
Q1 		$496K Hold
31,500
– – ﹤0.01% 2315
2018
Q4 		$634K Sell
31,500
-5,000
-14% -$110K ﹤0.01% 2158
2018
Q3 		$907K Hold
36,500
– – ﹤0.01% 2147
2018
Q2 		$1M Buy
36,500
+7,300
+25% +$219K ﹤0.01% 2098
2018
Q1 		$899K Buy
29,200
+538
+2% +$17.3K ﹤0.01% 2083
2017
Q4 		$1.02M Buy
28,662
+5,362
+23% +$154K ﹤0.01% 2016
2017
Q3 		$642K Hold
23,300
– – ﹤0.01% 2237
2017
Q2 		$615K Sell
23,300
-1
-0% -$22 ﹤0.01% 2309
2017
Q1 		$485K Buy
23,301
+4,401
+23% +$90.4K ﹤0.01% 2393
2016
Q4 		$391K Hold
18,900
– – ﹤0.01% 2478
2016
Q3 		$306K Hold
18,900
– – ﹤0.01% 2574
2016
Q2 		$257K Hold
18,900
– – ﹤0.01% 2607
2016
Q1 		$330K Buy
18,900
+2,300
+14% +$46.8K ﹤0.01% 2443
2015
Q4 		$567K Buy
16,600
+1,800
+12% +$62.4K ﹤0.01% 2252
2015
Q3 		$440K Buy
14,800
+1,062
+8% +$32.3K ﹤0.01% 2370
2015
Q2 		$439K Buy
+13,738
New +$353K ﹤0.01% 2570

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

New York State Common Retirement Fund's RVNC Position: Q1 2025 in Review

New York State Common Retirement Fund sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 31,338 shares — an estimated $95.3K sold.

New York State Common Retirement Fund first reported a position in RVNC in Q2 2015 and held it in 39 quarters. The position peaked at $1.8M in Q2 2021. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • New York State Common Retirement Fund reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • New York State Common Retirement Fund sold 31,338 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $95.3K.
  • New York State Common Retirement Fund first reported a position in Revance Therapeutics, Inc. in Q2 2015 and held it in 39 quarters.
  • New York State Common Retirement Fund's Revance Therapeutics, Inc. position peaked at $1.8M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on New York State Common Retirement Fund's 13F filing for Q1 2025, filed 1 May 2025.